Latest research on Lisdexamfetamine

Lisdexamfetamine (L-lysine-d-amphetamine) is a prodrug of the psychostimulant d-amphetamine coupled with the essential amino acid L-lysine. It was developed so that the amphetamine psychostimulant is released and activated more slowly as the prodrug molecule is hydrolyzed consequently cleaving off the amino acid-during the first pass through the intestines and/or the liver. Amphetamines target the trace amine-associated receptor 1 (TAAR1). Amphetamine is also believed to exert its effects by binding to the monoamine transporters (the dopamine transporter or DAT) and increasing extracellular levels of the biogenic amines dopamine, norepinephrine (noradrenaline) and serotonin.

Latest findings

The Dopamine agonist, ropinorole, was then initiated along with Lisdexamfetamine, which had been approved by the insurance company, so it was now possible to be increased to 70 mg a day. [source]
The patient stated, as had been her custom, that she had stopped the Lisdexamfetamine, two weeks prior to the last visit, for unclear reasons. [source]